Proteomics International is pleased to announce it has signed an exclusive licence agreement with Sonic Healthcare USA to commercialise the PromarkerD test for diabetic kidney disease.
With an estimated 32 million people living with type 2 diabetes, the US is a key market for PromarkerD.
